About: Lithium chloride confers protection against viral myocarditis via suppression of coxsackievirus B3 virus replication

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Lithium chloride confers protection against viral myocarditis via suppression of coxsackievirus B3 virus replication Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Lithium chloride confers protection against viral myocarditis via suppression of coxsackievirus B3 virus replication
Creator	Li, Min Xu, Wei Wei, Lin Cai, Jiamin Li, Shuijun Wang, Yanqi Yan, Kepeng Zhao, Yinxia
Source	Elsevier; Medline; PMC
abstract	Viral myocarditis (VMC) is a type of inflammation affecting myocardial cells caused by viral infection and has been an important cause of dilated cardiomyopathy (DCM) worldwide. Type B3 coxsackievirus (CVB3), a non-enveloped positive-strand RNA virus of the Enterovirus genus, is one of most common agent of viral myocarditis. Till now, effective treatments for VMC are lacking due to lack of drugs or vaccine. Lithium chloride (LiCl) is applied in the clinical management of manic depressive disorders. Accumulating evidence have demonstrated that LiCl, also as an effective antiviral drug, exhibited antiviral effects for specific viruses. However, there are few reports of evaluating LiCl’s antiviral effect in mice model. Here, we investigated the inhibitory influence of LiCl on the CVB3 replication in vitro and in vivo and the development of CVB3-induced VMC. We found that LiCl significantly suppressed CVB3 replication in HeLa via inhibiting virus-induced cell apoptosis. Moreover, LiCl treatment in vivo obviously inhibited virus replication within the myocardium and alleviated CVB3-induced acute myocarditis. Collectively, our data demonstrated that LiCl inhibited CVB3 replication and negatively regulated virus-triggered inflammatory responses. Our finding further expands the antiviral targets of LiCl and provides an alternative agent for viral myocarditis.
has issue date	2020-03-20(xsd:dateTime)
bibo:doi	10.1016/j.micpath.2020.104169
bibo:pmid	32205210
has license	no-cc
sha1sum (hex)	84b5baf8db08e8561ab8fb7dce587e42910975a9
schema:url	https://doi.org/10.1016/j.micpath.2020.104169
resource representing a document's title	Lithium chloride confers protection against viral myocarditis via suppression of coxsackievirus B3 virus replication
has PubMed Central identifier	PMC7102605
has PubMed identifier	32205210
schema:publication	Microb Pathog
resource representing a document's body	covid:84b5baf8db08e8561ab8fb7dce587e42910975a9#body_text
is schema:about of	named entity 'apoptosis' named entity 'HeLa' named entity 'inhibiting' named entity 'virus' named entity 'replication' named entity 'viruses' named entity 'ANTIVIRAL' named entity 'LACK' named entity 'TYPE' named entity 'TILL' named entity 'EFFECTS' named entity 'LACKING' named entity 'MICE' named entity 'VIRUSES' named entity 'MANIC DEPRESSIVE' named entity 'DUE TO' named entity 'FINDING' named entity 'REPLICATION' named entity 'TRIGGERED' named entity 'VIRUS REPLICATION' named entity 'ACCUMULATING' named entity 'COXSACKIEVIRUS' named entity 'DEMONSTRATED' named entity 'IN VITRO' named entity 'LITHIUM CHLORIDE' named entity 'DEVELOPMENT' named entity 'TARGETS' named entity 'HERE' named entity 'INDUCED' named entity 'INFLAMMATORY RESPONSES' named entity 'POSITIVE-STRAND RNA VIRUS' named entity 'PROVIDES' named entity 'COXSACKIEVIRUS B3' named entity 'VIRUS REPLICATION' named entity 'VIRAL MYOCARDITIS' named entity 'SUPPRESSION' named entity 'PROTECTION' named entity 'AGENT' named entity 'ONE OF' named entity 'SUPPRESSED' named entity 'TREATMENT' named entity 'INFLUENCE' named entity 'DILATED CARDIOMYOPATHY' named entity 'INHIBITING' named entity 'COMMON' named entity 'IN VIVO' named entity 'ENTEROVIRUS' named entity 'APPLIED' named entity 'WORLDWIDE' named entity 'VIRAL MYOCARDITIS' named entity 'CAUSE' named entity 'VACCINE' named entity 'ALTERNATIVE' named entity 'INVESTIGATED' named entity 'GENUS' named entity 'APOPTOSIS' named entity 'REPORTS' named entity 'VMC' named entity 'MYOCARDIUM' named entity 'DATA' named entity 'ACUTE MYOCARDITIS' named entity 'MODEL' named entity 'CLINICAL MANAGEMENT' named entity 'EFFECT' named entity 'CELL' named entity 'EFFECTIVE' named entity 'IMPORTANT' named entity 'FOUND' named entity 'DRUGS' named entity '27S' named entity 'HAVE' named entity 'INHIBITED' named entity 'SPECIFIC' named entity 'REGULATED'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software